CoChat

BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition

Open access

Published version of a preprint

The DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index.

Abstract

KRAS is the most frequently mutated driver of pancreatic, colorectal, and non–small cell lung cancers. Direct KRAS blockade has proved challenging, and inhibition of a key downstream effector pathway, the RAF–MEK–ERK cascade, has shown limited success because of activation of feedback networks that keep the pathway in check. We hypothesized that inhibiting SOS1, a KRAS activator and important feedback node, represents an effective approach to treat KRAS-driven cancers. We report the discovery of a highly potent, selective, and orally bioavailable small-molecule SOS1 inhibitor, BI-3406, that binds to the catalytic domain of SOS1, thereby preventing the interaction with KRAS. BI-3406 reduces formation of GTP-loaded RAS and limits cellular proliferation of a broad range of KRAS-driven cancers. Importantly, BI-3406 attenuates feedback reactivation induced by MEK inhibitors and thereby enhances sensitivity of KRAS-dependent cancers to MEK inhibition. Combined SOS1 and MEK inhibition represents a novel and effective therapeutic concept to address KRAS-driven tumors. Significance: To date, there are no effective targeted pan-KRAS therapies. In-depth characterization of BI-3406 activity and identification of MEK inhibitors as effective combination partners provide an attractive therapeutic concept for the majority of KRAS-mutant cancers, including those fueled by the most prevalent mutant KRAS oncoproteins, G12D, G12V, G12C, and G13D. See related commentary by Zhao et al., p. 17. This article is highlighted in the In This Issue feature, p. 1

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-20-0142

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

17 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 479

Metadata

Authors
Hofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., Sanderson, M. P., Kessler, D., Trapani, F., Arnhof, H., Rumpel, K., Botesteanu, D.-A., Ettmayer, P., Gerstberger, T., Kofink, C., Wunberg, T., Zoephel, A., Fu, S.-C., Teh, J. L., Böttcher, J., Pototschnig, N., Schachinger, F., Schipany, K., Lieb, S., Vellano, C. P., O'Connell, J. C., Mendes, R. L., Moll, J., Petronczki, M., Heffernan, T. P., Pearson, M., McConnell, D. B., & Kraut, N.
Affiliations
  • Boehringer Ingelheim (Austria) (AT)
  • 1Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • The University of Texas MD Anderson Cancer Center (US)
  • 4Forma Therapeutics, Watertown, Massachusetts.
  • Forma Therapeutics (United States) (US)
Venue
Cancer Discovery
Published
2021-01-01
Volume
11
Issue
1
Pages
142-157
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3077914340
Cited by
444
References
56
Citations by year
2026: 55 · 2025: 76 · 2024: 98 · 2023: 82 · 2022: 70 · 2021: 59
FWCI
17.83
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • DORA PSI (Paul Scherrer Institute) (submittedVersion)
Funders
  • Boehringer Ingelheim and the Austrian Research Promotion Agency (854341, 861507, 867897, 874517)
  • the MDACC Science Park NGS Core (RP170002)
  • NCI (#CA16672)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
SOS1 inhibitor, KRAS, MEK inhibition, Raf/MEK/ERK pathway, KRAS-driven cancers, KRAS G12C, KRAS G12D, KRAS G12V, KRAS G13D, combination therapy, small-molecule kinase inhibitors, pancreatic cancer, colorectal cancer, non-small cell lung cancer
MeSH terms
Humans, Lung Neoplasms, Mutation, Nucleotides, Proto-Oncogene Proteins p21(ras), Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. https://app.cochat.ai/papers/10.1158/2159-8290.cd-20-0142
The paper
Hofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., Sanderson, M. P., Kessler, D., Trapani, F., Arnhof, H., Rumpel, K., Botesteanu, D.-A., Ettmayer, P., Gerstberger, T., Kofink, C., Wunberg, T., Zoephel, A., Fu, S.-C., Teh, J. L., . . . Kraut, N. (2021). BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-20-0142

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.